Literature summary for 2.7.12.2 extracted from

Kojima, K.; Konopleva, M.; Samudio, I.J.; Ruvolo, V.; Andreeff, M.
Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells (2007), Cancer Res., 67, 3210-3219.

Search for more literature for 2.7.12.2

Application

Application	Comment	Organism
medicine	plays a role in acute myelogenous leukemia, Raf/MEK/ERK pathway regulates the subcellular localization of p53 and the relative contribution of transcription-dependent and transcription-independent pathways in p53-mediated apoptosis	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
PD98059	MEK-specific inhibitor, enhances antileukemia activity of Mdm2 antagonists in AML cells and p53-mediated transcription-dependent apoptosis. MEK inhibition accumulates p53 into the nucleus in OCIAML-3 cells, but does not affect the nucleoplasmic localization of Mdm2. The inhibitor restricts p21-mediated antiapoptotic mechanisms by repressing p53-dependent induction of p21, which enables Nutlin-3a to induce sufficient apoptosis in G1-phase cells	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
HL-60 cell	-	Homo sapiens	-
additional information	OCI-AML-3 cell and MOLM-13 cell	Homo sapiens	-

Synonyms

Synonyms	Comment	Organism
MEK	-	Homo sapiens
mitogen-activated protein kinase kinase	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)